Canada Markets close in 1 hr 30 mins

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2982+0.0032 (+1.08%)
As of 02:04PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.2950
Open0.3090
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2855 - 0.3210
52 Week Range0.1200 - 0.5100
Volume266,118
Avg. Volume598,587
Market Cap94.964M
Beta (5Y Monthly)0.05
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Baystreet

    Stocks in play: Revive Therapeutics Ltd

    Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

  • GlobeNewswire

    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUATORONTO, May 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “

  • GlobeNewswire

    PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

    Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)